Published in Eur J Pediatr on March 01, 2002
Pertussis re-emergence in the post-vaccination era. BMC Infect Dis (2013) 1.44
Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev (2016) 1.07
Bordetella pertussis evolution in the (functional) genomics era. Pathog Dis (2015) 0.87
Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. CMAJ (2006) 0.87
Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose. Eur J Pediatr (2005) 0.80
Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination. PLoS One (2016) 0.79
Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review. Vaccine (2015) 0.75
Clinical presentation of pertussis in fully immunized children in Lithuania. BMC Infect Dis (2005) 0.75
Immune persistence after pertussis vaccination. Hum Vaccin Immunother (2017) 0.75
Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev (2005) 6.02
Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med (2005) 3.21
Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J (2005) 2.06
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2010) 1.99
Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J (2006) 1.94
Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis (2006) 1.83
Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74
Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis (2008) 1.68
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine (2007) 1.66
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis (2004) 1.60
Varicella-zoster virus: an overlooked cause of aseptic meningitis. Pediatr Infect Dis J (2003) 1.52
Three-year surveillance of intussusception in children in Switzerland. Pediatrics (2007) 1.45
Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children. Eur J Pediatr (2010) 1.40
Influenza vaccination among healthcare workers in a university children's hospital. Infect Control Hosp Epidemiol (2005) 1.32
New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis (2004) 1.29
Why do pertussis vaccines fail? Pediatrics (2012) 1.27
Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J (2012) 1.19
The present and future control of pertussis. Clin Infect Dis (2010) 1.18
Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr (2005) 1.14
How do physicians immunize their own children? Differences among pediatricians and nonpediatricians. Pediatrics (2005) 1.13
Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013. Pediatr Infect Dis J (2015) 1.12
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine (2002) 1.11
Addressing the needs and gaps in safety assessment of vaccines during clinical trials in resource limited countries. Vaccine (2011) 1.09
Standardised case definitions for adverse events following immunisation. Lancet (2013) 1.09
A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants. Pediatrics (2004) 1.04
Intussusception: incidence and treatment-insights from the nationwide German surveillance. J Pediatr Gastroenterol Nutr (2011) 1.03
Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine (2011) 1.02
Health burden of pertussis in infants and children. Pediatr Infect Dis J (2005) 0.99
Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation (2005) 0.97
Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis (2004) 0.97
All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. Vaccine (2007) 0.95
Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine (2007) 0.94
Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis (2004) 0.94
Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine (2008) 0.94
Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents. Eur J Pediatr (2004) 0.93
Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine (2005) 0.93
Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol (2010) 0.93
Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J (2004) 0.92
Prospective pertussis surveillance in Switzerland, 1991-2006. Vaccine (2011) 0.91
Comparative coverage of supplementary and universally recommended immunizations in children at 24 months of age. Pediatr Infect Dis J (2012) 0.91
The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr (Phila) (2008) 0.90
No temporal association between influenza outbreaks and invasive pneumococcal infections. Arch Dis Child (2007) 0.90
A 4-year study on clinical characteristics of children hospitalized with rotavirus gastroenteritis. Eur J Pediatr (2009) 0.89
Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine (2007) 0.88
The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine (2007) 0.88
Etiology of aseptic meningitis, peripheral facial nerve palsy, and a combination of both in children. Pediatr Infect Dis J (2010) 0.87
Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine (2008) 0.86
Acceptance and timeliness of standard vaccination in children with chronic neurological deficits in north-western Switzerland. Eur J Pediatr (2005) 0.86
Mycobacterium bohemicum--a cause of paediatric cervical lymphadenitis. Swiss Med Wkly (2004) 0.86
Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines. Eur J Pediatr (2005) 0.85
Clinical findings and unusual epidemiologic characteristics of human metapneumovirus infections in children in the region of Basel, Switzerland. Eur J Pediatr (2007) 0.85
Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin (2009) 0.85
Rotavirus disease in Germany--a prospective survey of very severe cases. Pediatr Infect Dis J (2013) 0.85
A multicenter, cross-sectional study on the prevalence and risk factors for nasal colonization with Staphylococcus aureus in patients admitted to children's hospitals in Switzerland. Clin Infect Dis (2008) 0.85
Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine (2004) 0.84
Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin Vaccine Immunol (2006) 0.84
Age-related differences in patterns of increased Bordetella pertussis antibodies. Clin Vaccine Immunol (2012) 0.84
Template protocol for clinical trials investigating vaccines--focus on safety elements. Vaccine (2013) 0.84
Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels. Vaccine (2013) 0.84
Standardized case definitions of adverse events following immunization (AEFI). Vaccine (2004) 0.83
The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf (2003) 0.83
Immunity to pertussis. Clin Infect Dis (2007) 0.83
Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J (2005) 0.83
Adverse events following immunization: perception and evidence. Curr Opin Infect Dis (2007) 0.83
Prospective study on central venous line associated bloodstream infections. Arch Dis Child (2011) 0.82
Prospective surveillance of nosocomial viral infections during and after hospitalization at a university children's hospital. Pediatr Infect Dis J (2010) 0.82
Incidence and Outcome of Group B Streptococcal Sepsis in Infants in Switzerland. Pediatr Infect Dis J (2016) 0.81
Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr (2004) 0.81
Fever following immunization. Expert Rev Vaccines (2005) 0.81
Prevalence of nosocomial infections in Swiss children's hospitals. Infect Control Hosp Epidemiol (2004) 0.81
The Brighton Collaboration-enhancing vaccine safety. Vaccine (2004) 0.80
Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations. Expert Opin Biol Ther (2006) 0.80
Prospective surveillance of varicella-zoster virus infections in an out-patient setting in Switzerland. Hum Vaccin (2009) 0.80
Exchange blood transfusion in the management of severe pertussis in young infants. Pediatr Infect Dis J (2013) 0.79
Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. J Clin Virol (2007) 0.78
Evaluation of the Brighton Collaboration case definition of acute intussusception during active surveillance. Vaccine (2005) 0.78
A retrospective analysis of nosocomial viral gastrointestinal and respiratory tract infections. Pediatr Infect Dis J (2012) 0.78
Protection against vaccine-preventable diseases in medical students. Pediatr Infect Dis J (2003) 0.77
Interstrain antigenic variability of mumps viruses. Clin Infect Dis (2008) 0.77
Health care-associated rotavirus illness in pediatric inpatients in Germany, Austria, and Switzerland. Infect Control Hosp Epidemiol (2006) 0.77
Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial. PLoS One (2013) 0.77
Quadrivalent human vaccine - a call to action and for additional research. Pediatr Res (2007) 0.77
Interpretation of primary care physicians' attitude regarding rotavirus immunisation using diffusion of innovation theories. Vaccine (2009) 0.76
Recurrent papular urticaria after varicella immunization in a fifteen-month-old girl. Pediatr Infect Dis J (2005) 0.76
Protection against vaccine-preventable diseases in medical students: a follow up. Pediatr Infect Dis J (2014) 0.76
Pertussis Across the Globe: Recent Epidemiologic Trends From 2000-2013. Pediatr Infect Dis J (2015) 0.76
Can tacrolimus ointment (Protopic) exacerbate an intercurrent fungal infection? Pediatrics (2006) 0.75
Comment: clinical implications of endotoxin concentrations in vaccines. Ann Pharmacother (2002) 0.75
The protein content of diphtheria-tetanus toxoids-acellular pertussis vaccines and an emerging clinical problem. J Infect Dis (2005) 0.75
Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants. Vaccine (2005) 0.75
Comment on findings of Hodge et al. Respirology (2004) 0.75
Real-time fluorescence polymerase chain reaction (PCR) identification of Streptococcus pneumoniae from pleural fluid and tissue. Scand J Infect Dis (2005) 0.75
[On the articles published by Dr. Berndt regarding the HPV vaccination on 11/26/2008]. Pharm Unserer Zeit (2009) 0.75
Randomized, comparative efficacy trial of oral penicillin versus cefuroxime for perianal streptococcal dermatitis in children. J Pediatr (2008) 0.75